Compare TG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | VYGR |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 193.5M |
| IPO Year | 1994 | 2015 |
| Metric | TG | VYGR |
|---|---|---|
| Price | $7.21 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.89 |
| AVG Volume (30 Days) | 181.3K | ★ 844.6K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $800,821,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $129.75 |
| P/E Ratio | $23.62 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $6.25 | $1.75 |
| 52 Week High | $10.53 | $5.19 |
| Indicator | TG | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 25.95 |
| Support Level | $7.16 | N/A |
| Resistance Level | $8.21 | $4.34 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 17.32 | 1.29 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.